Skip to main content

Drug-Induced Hepatotoxicity!

 DRUG-INDUCED HEPATOTOXICITY

"Hepatotoxicity is the injury or liver damage caused by exposure to certain drugs, when taken in overdoses and sometimes when administered at therapeutic ranges, may injure the organ".

  • Drug-induced hepatotoxicity is also referred to as the Drug-Induced Liver Injury (DILI).

Physiological functions of liver:

  1. Formation and sensation of bile.
  2. Nutrient and vitamin metabolism (amino acid, lipid).
  3. Detoxification and inactivation of various substances (toxin drugs).
  4. Synthesis of plasma proteins (Albumin, clotting factors).
  5. Immune systems (Kupffer cells).

  • Hepatotoxicity is most prevalent in older patients especially in those with pre-existing hepatic impairment.


The few examples of drugs that cause hepatotoxicity are listed below:

1. ACE Inhibitors:

  • Hepatic injury occurs occasionally with ACE-Inhibitors.
  • Captopril and Enalapril are implicated in most reported cases, but others also have similar hepatotoxic potential.
  • Most cases show cholestatic injury, but mixed and hepatocellular damage are also reported.

2. Acetaminophen:

  • Acetaminophen is a widely used drug found in many over the counter and prescription analgesics medicine.
  • In adults, toxicity may occur by ingestion of >7.5-10 g over a period of 8hrs. or less.
  • Acetaminophen is metabolized in the liver by conjugation to non-toxic glutathione. The conjugated product is eliminated in urine. But in acute overdoses, the livers normal glutathione reserves are depleted, and the excess acetaminophen is then metabolized to highly toxic metabolite N-Acetyl-p-benzoquinone (NABQI), causing hepatocellular death and liver cell necrosis.
  • Alcohol consumption increase Acetaminophen toxicity.
  • Hepatitis is reported in patients taking large Acetaminophen doses for therapeutic purposes.


3. Alcohol:

  • Ethanol is oxidized in liver to Acetaldehyde that results in injury to cells and mitochondria with striking impairment of O2 utilization.
  • Fatty infiltration of liver occurs in 70-100% of alcoholic.
  • 30% alcoholics develop alcoholic hepatitis and 10% develop liver cirrhosis.
  • Alcohol can also enhance the hepatotoxicity of other drugs.
  • Malnutrition can potentiate alcoholic disease.


4. Antidepressants, Heterocyclics:

  • The prevalence of hepatic injury is estimated to be 1%; with most cases presenting as cholestasis.
  • The idiosyncratic reaction resembles the cholestasis associated with Phenothiazine.


5. Cephalosporins:

  • Transient-minor increase in AST, ALT, and Alkaline phosphate occur frequently.
  • Ceftriaxone use is associated with development of "gallbladder sludge" in up to 25% of patients.


6. Contraceptives, Oral:

  • Data from two large, long-term cohort studies did not detect any association between oral contraceptives use and serious liver disease.
  • One study detected an increase in the frequency of mild-liver diseases among users of older, high estrogen products.
  • Frequency of gall-bladder disease was also increased by older oral contraceptives.


7. Gold-Salts:

  • Cholestasis occur occasionally with normal doses of parenteral gold salts.
  • Hypersensitivity is the suspected mechanism.
  • Onset is commonly with first few weeks of therapy and recovery usually occur 3 months after drug discontinuation.
  • Lipo-granulomas are frequently found in liver biopsy of parenteral gold-treated patients.
  • Hepatic necrosis can result from overdose.


8. Histamine H2-Receptor Antagonists:

  • Cimetidine and Ranitidine are associated with increased liver enzymes.
  • Risk of acute liver injury (ALI) with cimetidine is about 1/5000 with most cases occurring during first 2 months of use.


9. NSAIDs:

  • The incidence of clinically apparent hepatic injury from non-salicylates NSAIDs estimated to be 1/10000 patients.
  • The incidence for Sulindac may be 5-10 times higher than for other non-salicylate NSAIDs. 50% reaction to Sulindac are cholestatic 25% hepatocellular.

10. Penicillin:

  • Cloxacillin and Flucloxacillin are associated with cholestatic hepatitis.
  • The effect is reversible but can persist for months after drug discontinuation.


11. Steroids, C-17-a-Alkyl:

  • Canalicular cholestasis occurs with a minimal amount of hepatic inflammation.
  • Prevalence appears to be dose related.
  • Jaundice may or may not be preceded by clinical signs and usually follows 1-6 months therapy.
  • Examples are: Methyltestosterone, Oxymetholone, Oxandrolone.


12. Vitamin A:

  • Hepatomegaly, portal hypertension and mild increase in liver enzyme leads are common features of Vitamin A.
  • Central vein sclerosis and perisinusoidal fibrosis which can progress to cirrhosis have also been reported in Vit-A toxicity. These affects are associated with doses >50000 IU/day.
  • Hepatotoxicity is possible with acute doses >600000IU/day.

Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Pharmacotherapy-TZDs!

  PHARMACOTHERAPY: THIAZOLIDINEDIONES Commonly referred to as TZDs or Glitazones , Thiazolidinediones have established a role in T2DM Therapy. Mechanism of Action: TZDs are known to increase insulin sensitivity by stimulating peroxisome proliferator-activated receptor gamma (PPAR-g). Stimulation of PPAR-g results in a number of intracellular and extracellular changes including increased insulin sensitivity and decreased plasma fatty acid levels. Pharmacokinetics: The onset of TZDs is delayed for several weeks and require up ton 12 weeks before maximum effects are observed. Therapy: As monotherapy , TZDs reduce FPG levels by around 60-70mg/dL and the effect of A1c is up to 1.5% reduction. Clinical Uses: Pioglitazone and Rosiglitazone increases HDL . Pioglitazone increases HDL by 5.2mg/dL Rosiglitazone increases HDL levels by 2-4mg/dL. Pioglitazone decreases serum Triglyceride s by an average of 51.9mg/dL. Rosiglitazone increases serum triglycerides. Pioglitazone increases LDL leve...
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Glinides and Biguanides!

 PHARMACOTHERAPY 2.NONSULFONYLUREA SECRETAGOGUES (GLINIDES) Although producing the same effects as sulfonyl ureas, Non sulfonylurea secretogogues also referred to as Glinides or Meglitinides have rapid onset and short duration of action. Mechanism of Action: Glinides produce a pharmacological action by interacting with ATP-Sensitive potassium channels on the beta cells; however, this binding is to a receptor adjacent to those with which the sulfonyl ureas bind. Clinical Uses: The primary benefit is in reducing post-meal glucose levels. These agents have resulted in a reduction of 0.8-1% A1c levels. Indications: Because they have a rapid onset of action, Glinides are supposed to be taken 15-30 minutes before the meal. Therapy: They may also be used in combination therapy with other drugs to achieve synergistic effects. Combinations with Biguanides is mostly used. 3.BIGUANIDES Biguanides include Metformin as the Drug of choice for T 2 DM. Mechanism of Actions: Biguanides are though...
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- SGLT, Centrally Acting Dopamine Agonists & Bile Acid Sequestrants!

 PHARMACOTHERAPY: Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 7.SODIUM-GLUCOSE CO-TRANPORTER (SGLT-2) INHIBITORS The drugs approved include Canagliflozin, Dapagliflozin, Empagliflozin . Mechanism of Action: Glucose is freely filtered buy the kidney glomeruli and is reabsorbed in the proximal convoluted tubules by the action of sodium glucose co-transporters (SGLT). SGLT accounts for 90% of the glucose reabsorption and its inhibition causes glycosuria in people with diabetes, lowering plasma glucose levels. Dose: Canagliflozin: 100 & 300mg - 100mg daily if usual dose. 300mg daily can be used if eGFR resulting in lowering HDL.  Dapagliflozin: 3 & 10mg - 10 mg daily. 3mg daily in hepatic fai...
Post a Comment
Read more